help shape patient care worldwide
As a leading innovation-driven organisation, Lilly is developing a growing portfolio of pharmaceutical products focused on meeting some of the world's most urgent medical needs in the fields of cardiovascular disease, diabetes, endocrine, musculoskeletal disease, neuroscience, oncology and urology.
Our commitment to innovation and care does not stop with humans. Elanco, a division of Lilly, is committed to quality care and product innovation for animals through protein production, companion animal health, and food safety.
UK laws and regulations limit the amount of product information that we can provide to the general public via our website. The product information on this website is intended for UK residents over the age of eighteen years only.
Reporting Of Side Effects
Please do not use this website to report side effects or complaints about a Lilly product. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of medicines.
The following Lilly medicines are subject to additional monitoring: Abasaglar®, Amyvid®, Cyramza®, Jardiance®, Jentadueto®, Lartruvo®, Olumiant®, Portrazza®, Taltz®, Trajenta®, Trulicity® and Synjardy®. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
Lilly’s Medical Information team can be contacted on 01256 315 000.
* Lilly is the marketing authorisation holder (MAH) but either co promotes or co markets this product
** Lilly is not the marketing authorisation holder (MAH) but either promotes, markets or distributes this product
*** Lilly is the marketing authorisation holder (MAH) but does not promote this product